Thomas Mann
Internal Medicine · Fitzgerald, GANPI 1740370691
Payments from drug & device makers
Across 238 payments — averaging $17.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$709
- Novo Nordisk$673
- AbbVie$587
- AstraZeneca$415
- Astellas Pharma US Inc$270
- Lilly USA, LLC$180
- plus $1K from 25 others
What the payments were for
- Food & beverage$4,01298%
- Education$912%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 35 | $709 |
| Novo Nordisk | 35 | $673 |
| AbbVie(2 entities) | 45 | $587 |
| AstraZeneca | 26 | $415 |
| Astellas Pharma US Inc | 10 | $270 |
| Lilly USA, LLC | 11 | $180 |
| Johnson & Johnson | 15 | $164 |
| Axsome Therapeutics, Inc. | 4 | $116 |
| Takeda Pharmaceuticals U.S.A., Inc. | 8 | $106 |
| Bayer | 4 | $82 |
| Pfizer | 5 | $81 |
| Sanofi-aventis U.S. LLC | 4 | $70 |
| Sunovion Pharmaceuticals Inc. | 3 | $67 |
| Boehringer Ingelheim | 4 | $64 |
| Ardelyx, Inc. | 2 | $57 |
| Dexcom, Inc. | 2 | $47 |
| Novartis | 3 | $46 |
| Idorsia Pharmaceuticals US Inc | 3 | $44 |
| Sumitomo Pharma America, Inc. | 3 | $44 |
| Otsuka America Pharmaceutical, Inc. | 2 | $43 |
| Xeris Pharmaceuticals, Inc. | 2 | $42 |
| Eisai Inc. | 2 | $35 |
| Vanda Pharmaceuticals Inc. | 1 | $32 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $25 |
| Exact Sciences | 1 | $21 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $16 |
| Phathom Pharmaceuticals, Inc. | 2 | $15 |
| Boston Scientific | 1 | $15 |
| Corium, LLC | 1 | $13 |
| C. R. Bard, Inc. & Subsidiaries | 1 | $13 |
| E.r. Squibb & Sons, L.L.C. | 1 | $12 |
How this compares
$4,103 in reported general payments places this provider in the 85th percentile of 3,311 internal medicine providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 152 | $184,733 |
| EliquisApixaban | 167 | $147,895 |
| OzempicSemaglutide | 111 | $135,364 |
| JardianceEmpagliflozin | 109 | $97,842 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 89 | $70,633 |
| Tresiba Flextouch U-100Insulin Degludec | 101 | $55,117 |
| XareltoRivaroxaban | 53 | $49,621 |
| VraylarCariprazine Hcl | 26 | $46,709 |
| LinzessLinaclotide | 62 | $42,409 |
| TradjentaLinagliptin | 51 | $41,844 |
| FarxigaDapagliflozin Propanediol | 33 | $28,772 |
| Tresiba Flextouch U-200Insulin Degludec | 18 | $27,335 |
| JanuviaSitagliptin Phosphate | 40 | $25,792 |
| BelsomraSuvorexant | 50 | $25,530 |
| TrulicityDulaglutide | 12 | $23,105 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $180 | $207,839164 claims |
| Boehringer IngelheimJardiance, Tradjenta, Stiolto Respimat, Combivent Respimat | $64 | $155,021189 claims |
| PfizerEliquis | $81 | $147,895167 claims |
| Novo NordiskOzempic | $673 | $135,364111 claims |
| AbbVieVraylar, Linzess | $587 | $89,11888 claims |
| GSKTrelegy Ellipta, Shingrix, Breo Ellipta | $709 | $84,443141 claims |
| Johnson & JohnsonXarelto | $164 | $49,62153 claims |
| AstraZenecaFarxiga, Symbicort | $415 | $34,67249 claims |
| Axsome Therapeutics, Inc.Auvelity | $116 | $17,39816 claims |
| Astellas Pharma US IncMyrbetriq | $270 | $16,16229 claims |
| NovartisEntresto | $46 | $13,03016 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $106 | $10,50616 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 3,311 internal medicine providers in Georgia.
Other internal medicine in Fitzgerald
- Paul BradleySavannah$76.4M
- Kimball JohnsonAtlanta$51.1M
- Bram WieskopfWoodstock$21.9M
- Dwight BlakeUnion City$13.3M
- Charlotte Grayson-MathisFayetteville$9.6M
- Christopher RecknorGainesville$9.2M
- James HarperJohns Creek$9.2M
- Robert Springer IiiAtlanta$5.3M
- Thomas MoriaritySavannah$4.6M
- Charles KempAlbany$2.7M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.